View Item 

Show simple item record

Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma

dc.contributor.authorLao, Xiang‐mingen_US
dc.contributor.authorWang, Dianen_US
dc.contributor.authorShi, Mingen_US
dc.contributor.authorLiu, Guipengen_US
dc.contributor.authorLi, Shengpingen_US
dc.contributor.authorGuo, Rongpingen_US
dc.contributor.authorYuan, Yunfeien_US
dc.contributor.authorChen, Minshanen_US
dc.contributor.authorLi, Jinqingen_US
dc.contributor.authorZhang, Yaqien_US
dc.contributor.authorLin, Xiaojunen_US
dc.date.accessioned2011-11-10T15:31:04Z
dc.date.available2012-07-12T17:42:23Zen_US
dc.date.issued2011-06en_US
dc.identifier.citationLao, Xiang‐ming ; Wang, Dian; Shi, Ming; Liu, Guipeng; Li, Shengping; Guo, Rongping; Yuan, Yunfei; Chen, Minshan; Li, Jinqing; Zhang, Yaqi; Lin, Xiaojun (2011). "Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma." Hepatology Research 41(6). <http://hdl.handle.net/2027.42/86805>en_US
dc.identifier.issn1386-6346en_US
dc.identifier.issn1872-034Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/86805
dc.publisherBlackwell Publishing Asiaen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherHepatitis B Virus Reactivationen_US
dc.subject.otherHepatitis B Virus DNAen_US
dc.subject.otherHepatocellular Carcinomaen_US
dc.subject.otherLiver Functionen_US
dc.subject.otherTranscatheter Arterial Chemoembolizationen_US
dc.titleChanges in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinomaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Surgical Oncology of University of Michiganen_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationotherDepartment of Hepatobilliary Oncology, Sun Yat‐sen University Cancer Center and State Key Laboratory of Southern China, Guangzhou, Chinaen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/86805/1/j.1872-034X.2011.00796.x.pdf
dc.identifier.doi10.1111/j.1872-034X.2011.00796.xen_US
dc.identifier.sourceHepatology Researchen_US
dc.identifier.citedreferenceParkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74 – 108.en_US
dc.identifier.citedreferenceBeasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129 – 33.en_US
dc.identifier.citedreferenceLlovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734 – 9.en_US
dc.identifier.citedreferenceYuen MF, Chan AO, Wong BC et al. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child‐Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol 2003; 98: 1181 – 5.en_US
dc.identifier.citedreferenceLalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699 – 712.en_US
dc.identifier.citedreferenceEuropean Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227 – 42.en_US
dc.identifier.citedreferenceBruix J, Llovet JM. Hepatitis B virus and hepatocellular carcinoma. J Hepatol 2003; 39 (Suppl 1 ): S59 – 63.en_US
dc.identifier.citedreferenceJang JW, Choi JY, Bae SH et al. Transarterial chemo‐lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004; 41: 427 – 35.en_US
dc.identifier.citedreferenceJang JW, Choi JY, Bae SH et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo‐lipiodolization. Hepatology 2006; 43: 233 – 40.en_US
dc.identifier.citedreferenceVizzini GB, Luca A, Marino IR. Hepatitis B virus reactivation after a single session of transarterial chemoembolization in patients with hepatocellular carcinoma. Ann Intern Med 2003; 138: 691 – 2.en_US
dc.identifier.citedreferencePark JW, Park KW, Cho SH et al. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV‐related hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol 2005; 100: 2194 – 200.en_US
dc.identifier.citedreferenceAhmad J, Rhee J, Carr BI. The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinoma. Dig Dis Sci 2005; 50: 331 – 5.en_US
dc.identifier.citedreferenceNagamatsu H, Kumashiro R, Itano S, Matsugaki S, Sata M. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV‐related HCC. Hepatol Res 2003; 26: 293 – 301.en_US
dc.identifier.citedreferenceXu J, Wang YH, Xia JL, Ge NL, Chen Y, Ye SL. [Effect of transcatheter arterial chemoembolization on HBV DNA level in primary liver cancer patients.]. Chin J Cancer 2009; 28: 520 – 3.en_US
dc.identifier.citedreferenceShi M, Chen JA, Lin XJ et al. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World J Gastroenterol 2010; 16: 264 – 9.en_US
dc.identifier.citedreferenceYeo W, Lam KC, Zee B et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004; 15: 1661 – 6.en_US
dc.identifier.citedreferenceYeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209 – 20.en_US
dc.identifier.citedreferenceYeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299 – 307.en_US
dc.identifier.citedreferenceTamori A, Nishiguchi S, Tanaka M et al. Lamivudine therapy for hepatitis B virus reactivation in a patient receiving intra‐arterial chemotherapy for advanced hepatocellular carcinoma. Hepatol Res 2003; 26: 77 – 80.en_US
dc.identifier.citedreferenceHung HH, Su CW, Wu JC, Lee SD. Reactivation of hepatitis B virus after transarterial chemo‐embolization for hepatocellular carcinoma in one patient with negative hepatitis B surface antigen. J Hepatol 2010; 52: 463 – 5.en_US
dc.identifier.citedreferenceLu W, Li YH, Yu ZJ et al. A comparative study of damage to liver function after TACE with use of low‐dose versus conventional‐dose of anticancer drugs in hepatocellular carcinoma. Hepatogastroenterology 2007; 54: 1499 – 502.en_US
dc.identifier.citedreferenceLiaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 1998; 13: 14 – 20.en_US
dc.identifier.citedreferenceCheng AL, Hsiung CA, Su IJ et al. Steroid‐free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV‐carriers with lymphoma. Hepatology 2003; 37: 1320 – 8.en_US
dc.identifier.citedreferenceCarman WF, Fagan EA, Hadziyannis S et al. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology 1991; 14: 219 – 22.en_US
dc.identifier.citedreferenceWu IC, Chow NH, Cheng PN et al. Characterization of viral kinetics in patients with hepatitis B e antigen‐positive chronic hepatitis B. J Med Virol 2007; 79: 663 – 9.en_US
dc.identifier.citedreferenceLok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182 – 8.en_US
dc.identifier.citedreferenceCaturelli E, Siena DA, Fusilli S et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue‐long‐term prospective study. Radiology 2000; 215: 123 – 8.en_US
dc.identifier.citedreferenceChan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002; 94: 1747 – 52.en_US
dc.identifier.citedreferenceHuo TI, Wu JC, Lee PC, Chang FY, Lee SD. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int 2004; 24: 210 – 15.en_US
dc.identifier.citedreferenceHuo TI, Lee SD, Wu JC. Hepatitis after arterial embolization for hepatocellular carcinoma: viral reactivation or ischemia? Hepatology 2006; 43: 1400 – 1.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1872-034X.2011.00796.x.pdf
Size:
439.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.